REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study is testing a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see if the combination can shrink or control the cancer. About…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 12:01 UTC
-
New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
Disease control TerminatedThis phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New combo therapy aims to unmask lymphoma cells and boost immune attack
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab—in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune system, wh…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can safely improve outcomes for adults with large B-cell lymphoma that has returned or stopped responding to treatment. The drug is designed to strengthen the immune sy…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC